

World Journal of *Hepatology*

World J Hepatol 2019 June 27; 11(6): 489-561



**REVIEW**

- 489** Dietary approach and gut microbiota modulation for chronic hepatic encephalopathy in cirrhosis
Campion D, Giovo I, Ponzo P, Saracco GM, Balzola F, Alessandria C
- 513** Outcomes of staged hepatectomies for liver malignancy
Albati NA, Korairi AA, Al Hasan I, Almodhaiberi HK, Algarni AA

ORIGINAL ARTICLE**Basic Study**

- 522** Proton pump inhibitors increase the severity of hepatic encephalopathy in cirrhotic patients
Fasullo M, Rau P, Liu DQ, Holzwanger E, Mathew JP, Guilarte-Walker Y, Szabo G

Retrospective Cohort Study

- 531** Efficacy of long-term rifaximin treatment for hepatic encephalopathy in the Japanese
Nishida S, Hamada K, Nishino N, Fukushima D, Koyanagi R, Horikawa Y, Shiwa Y, Saitoh S

Retrospective Study

- 542** Validation of modified albumin-bilirubin-TNM score as a prognostic model to evaluate patients with hepatocellular carcinoma
Elshaarawy O, Alkhatib A, Elhelbawy M, Gomaa A, Allam N, Alsebaey A, Rewisha E, Waked I
- 553** Risk factors for ribavirin treatment failure in Asian organ transplant recipients with chronic hepatitis E infection
Low EXS, Tripon E, Lim K, Tan PS, Low HC, Dan YY, Lee YM, Muthiah M, Loo WM, Koh CJ, Phyo WW, Pang J, Lim SG, Lee GH

ABOUT COVER

Associate Editor of *World Journal of Hepatology*, Calvin Pan, FACC, MD, Professor, New York University School of Medicine, Los Angeles, NY 10016, United States

AIMS AND SCOPE

The primary aim of *World Journal of Hepatology* (WJH, *World J Hepatol*) is to provide scholars and readers from various fields of hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJH mainly publishes articles reporting research results and findings obtained in the field of hepatology and covering a wide range of topics including chronic cholestatic liver diseases, cirrhosis and its complications, clinical alcoholic liver disease, drug induced liver disease autoimmune, fatty liver disease, genetic and pediatric liver diseases, hepatocellular carcinoma, hepatic stellate cells and fibrosis, liver immunology, liver regeneration, hepatic surgery, liver transplantation, biliary tract pathophysiology, non-invasive markers of liver fibrosis, viral hepatitis.

INDEXING/ABSTRACTING

The WJH is now abstracted and indexed in PubMed, PubMed Central, Emerging Sources Citation Index (Web of Science), Scopus, China National Knowledge Infrastructure (CNKI), China Science and Technology Journal Database (CSTJ), and Superstar Journals Database.

RESPONSIBLE EDITORS FOR THIS ISSUE

Responsible Electronic Editor: *Yan-Liang Zhang*

Proofing Production Department Director: *Yun-Xiaojuan Wu*

Responsible Editorial Office Director: *Ya-Juan Ma*

NAME OF JOURNAL

World Journal of Hepatology

ISSN

ISSN 1948-5182 (online)

LAUNCH DATE

October 31, 2009

FREQUENCY

Monthly

EDITORS-IN-CHIEF

Ke-Qin Hu, Koo Jeong Kang, Nikolaos Pyrsopoulos

EDITORIAL BOARD MEMBERS

<https://www.wjgnet.com/1948-5182/editorialboard.htm>

PUBLICATION DATE

June 27, 2019

COPYRIGHT

© 2020 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>

Basic Study

Proton pump inhibitors increase the severity of hepatic encephalopathy in cirrhotic patients

Matthew Fasullo, Prashanth Rau, Dong-Qi Liu, Erik Holzwanger, Jomol P Mathew, Yurima Guilarte-Walker, Gyongyi Szabo

ORCID number: Matthew Fasullo (0000-0003-3787-7626); Prashanth Rau (0000-0003-2026-1059); Dong-Qi Liu (0000-0002-6939-5376); Erik Holzwanger (0000-0001-7747-7729); Jomol P Mathew (0000-0002-6623-3689); Yurima Guilarte-Walker (0000-0003-3610-0452); Gyongyi Szabo (0000-0003-0836-2527).

Author contributions: Fasullo M designed the study and wrote the manuscript; Rau P, Liu DQ and Holzwanger E helped edit the paper and assisted with statistical analysis; Mathew JP and Guilarte-Walker Y assisted with data collection and defining the patient population; Szabo G was the senior author, provided concepts and oversight for the study design, data acquisition, interpretation and editing of the manuscript.

Institutional review board

statement: The study was reviewed and approved by the University of Massachusetts Medical School Institutional Review Board Approved Protocol (H00012102).

Informed consent statement: This study was approved by the UMMS IRB. Because this was performed as a retrospective study using data assembled from electronic health records based on waiver of consent from the IRB, individual consents were not obtained.

Conflict-of-interest statement:

Gyongyi Szabo received research funding from the National Institute for Alcoholism and Alcohol Abuse,

Matthew Fasullo, Prashanth Rau, Dong-Qi Liu, Erik Holzwanger, Gyongyi Szabo, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01605, United States

Jomol P Mathew, Department of Population and Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, MA 01605, United States

Yurima Guilarte-Walker, Department of Data Sciences and Technology, Information Technology, University of Massachusetts Medical School, Worcester, MA 01605, United States

Corresponding author: Gyongyi Szabo, MD, PhD, Professor, Department of Medicine, University of Massachusetts Medical School, 364 Planation Street, Worcester, MA 01605, United States. gyongyi.szabo@umassmed.edu
Telephone: +1-508-8565275

Abstract

BACKGROUND

Liver cirrhosis is the late stage of hepatic fibrosis and is characterized by portal hypertension that can clinically lead to decompensation in the form of ascites, esophageal/ gastric varices or encephalopathy. The most common sequelae associated with liver cirrhosis are neurologic and neuropsychiatric impairments labeled as hepatic encephalopathy (HE). Well established triggers for HE include infection, gastrointestinal bleeding, constipation, and medications. Alterations to the gut microbiome is one of the leading ammonia producers in the body, and therefore may make patients more susceptible to HE.

AIM

To investigate the relationship between the use of proton pump inhibitors (PPIs) and HE in patients with cirrhosis.

METHODS

This is a single center, retrospective analysis. Patients were included in the study with an admitting diagnosis of HE. The degree of HE was determined from subjective and objective portions of hospital admission notes using the West Haven Criteria. The primary outcome of the study was to evaluate the grade of HE in PPI users *versus* non-users at admission to the hospital and throughout their hospital course. Secondary outcomes included rate of infection, gastrointestinal bleeding within the last 12 mo, mean ammonia level, and model for end-stage liver disease scores at admission.

Intercept, Tobira, Signablock and Gilead. GS is a consultant for TerraFirma, Glympse, Quest Diagnostics, Allergan, Arrow Diagnostics, Salix and GLG. No other potential conflicts of interest relevant to this article were reported.

Open-Access: This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Manuscript source: Unsolicited manuscript

Received: January 16, 2019

Peer-review started: January 17, 2019

First decision: March 5, 2019

Revised: April 26, 2019

Accepted: June 17, 2019

Article in press: June 17, 2019

Published online: June 27, 2019

P-Reviewer: Bouare N, Soldara J

S-Editor: Cui LJ

L-Editor: Filipodia

E-Editor: Zhang YL



RESULTS

The HE grade at admission using the West Haven Criteria was 2.3 in the PPI group compared to 1.7 in the PPI nonuser group ($P = 0.001$). The average length of hospital stay in PPI group was 8.3 d compared to 6.5 d in PPI nonusers ($P = 0.046$). Twenty-seven (31.8%) patients in the PPI user group required an Intensive Care Unit admission during their hospital course compared to 6 in the PPI nonuser group (16.7%) ($P = 0.138$). Finally, 10 (11.8%) patients in the PPI group expired during their hospital stay compared to 1 in the PPI nonuser group (2.8%) ($P = 0.220$).

CONCLUSION

Chronic PPI use in cirrhotic patients is associated with significantly higher average West Haven Criteria for HE compared to patients that do not use PPIs.

Key words: Cirrhosis; Hepatic encephalopathy; Proton pump inhibitors; Hepatology; Proton pump inhibitor

©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: In this study, we investigate whether proton pump inhibitor (PPI) use in hepatic encephalopathy patients predisposes them to more severe stages of hepatic encephalopathy as per West Haven Criteria. We found that chronic PPI use in cirrhotic patients is associated with significantly higher average West Haven Criteria for hepatic encephalopathy compared to patients that did not use PPIs. Our data also indicated that cirrhotic patients on PPIs have longer hospital stays, with increased morbidity and mortality during their hospital stays.

Citation: Fasullo M, Rau P, Liu DQ, Holzwanger E, Mathew JP, Guilarte-Walker Y, Szabo G. Proton pump inhibitors increase the severity of hepatic encephalopathy in cirrhotic patients. *World J Hepatol* 2019; 11(6): 522-530

URL: <https://www.wjnet.com/1948-5182/full/v11/i6/522.htm>

DOI: <https://dx.doi.org/10.4254/wjh.v11.i6.522>

INTRODUCTION

Liver cirrhosis is a late stage of hepatic fibrosis and is characterized by portal hypertension that can clinically lead to decompensation in the form of ascites, esophageal/gastric varices or encephalopathy. There are multiple etiologies of liver cirrhosis, with Hepatitis C, alcoholic hepatitis/alcoholic liver disease and non-alcoholic fatty liver disease being the most common causes in the developed world^[1]. Some of the most common sequelae associated with liver cirrhosis are neurologic and neuropsychiatric impairments labeled as hepatic encephalopathy (HE). Neuropsychiatric changes associated with liver disease were first described by Adams and Foley in the 1940s and 1950s^[2]. Since then, our understanding of what HE entails and what precipitates it has only marginally grown. According to the currently accepted definition, HE is a neuropsychiatric disorder that can encompass a broad spectrum of presentations summarized in the West Haven Criteria Severity Scale. HE spans from minimal to Grade I (mild confusion, disordered sleep), through Grades II (lethargy, moderate confusion), III (marked confusion, incoherent speech) and finally Grade IV (coma)^[3,4].

While liver cirrhosis can predispose a patient to HE, there are additional triggers that can precipitate it or worsen its severity. Well established triggers include infection, gastrointestinal (GI) bleeding, constipation, and medications such as opioids and benzodiazepines^[5-8]. New studies have cited other etiologies, including changes in gut flora and small bowel bacterial overgrowth^[9,10]. More recently, there have been studies on the role of proton pump inhibitors (PPIs) in contributing to HE in cirrhotic patients. PPIs are commonly prescribed for many GI diseases, most commonly gastroesophageal reflux disease (commonly known as GERD), peptic ulcer disease, and gastritis^[11]. In contrast to previous beliefs, recent data suggests that PPIs have the potential for multiple adverse effects. PPIs act by decreasing gastric acid secretion, which is believed to be protective against acid-related mucosal injury in the

stomach^[12]. It was thought that their ability to protect the GI mucosa would mitigate the number of GI bleeds in cirrhotic patients, therefore reducing their risk of HE. However, new studies show that in addition to their direct effects in the stomach, PPIs may affect composition of the gut microbiome while also promoting small bowel bacterial overgrowth^[13].

Normally, nitrogenous compounds formed by the gut are drained into the portal system and filtered by the liver^[14]. These compounds then enter the urea cycle and are excreted in urine. However, in patients with liver disease, ammonia clearance is compromised due to reduced liver function and increased portosystemic shunting, leading to high levels of ammonia in the blood stream. When ammonia reaches the brain, it is metabolized by astrocytes and transformed from glutamate to glutamine *via* glutamine synthase. Accumulation of glutamine increases intracellular oncotic pressure, leading to cerebral edema. In patients with chronic liver disease, this cerebral edema can be subtle, and at this time, the edema alone does not explain all the findings of HE^[15-17]. However, the morphological changes seen with astrocyte swelling are similar to the changes seen in Type II Alzheimer's disease^[18]. Therefore, given the current mechanisms, it appears that ammonia levels (and subsequently astrocyte glutamine levels) have an overall neurotoxic effect.

Studies have shown that an increased gastric pH allows for increased gut microflora. In turn this can lead to increased bacterial translocation. Microflora species such as *Salmonella*, *Campylobacter jejuni*, *Escherichia coli*, *Clostridium difficile*, *Vibrio cholerae* and *Listeria* all appear to proliferate in high gastric pH^[13]. In addition, the literature suggests that more severe bacterial proliferation such as small intestinal bacterial overgrowth has also been linked with gastric hypochlorhydria secondary to prolonged PPI use. Overall, it does appear that elevation of gastric pH allows for greater gut bacterial proliferation. Increased proliferation is not without consequence, as the gut microbiome is one of the leading ammonia producers in the body, and therefore may make patients more susceptible to HE, which is what we believe to be the driving force behind our findings. This would partly explain why rifaximin, a poorly absorbable synthetic antibiotic, can lower the risk of HE in cirrhotic patients by affecting the gut microbiota. Given that changes in gut flora may lead to worse HE, the role of PPIs must be reconsidered. This study investigates whether PPI use in HE patients predisposes them to more severe stages of HE as per the West Haven Criteria.

MATERIALS AND METHODS

Patient selection

This retrospective medical chart review was conducted at the UMass Memorial Medical Center. Records for patients who presented with acute HE between January 1, 2012 and January 1, 2016 were reviewed. Patients were included in the study with an admitting diagnosis of HE with and without coma with ICD-9 code 572.2 and ICD-10 codes K72.00 and K72.01.

Eligible patients were ≥ 18 years of age, had prior history of End Stage Liver Disease or cirrhosis as determined by consistent image findings and/or liver biopsy. Patients were on PPIs for a minimum of 30 d prior to hospital admission. Exclusion criteria included pregnancy, current prisoner, failure to sign consent, and concomitant diagnosis of human immunodeficiency virus.

Data collection

Utilizing medical record and data from Electronic Health Records, demographics (age, sex), grade of HE, Model End Stage Liver Disease (MELD) score, Length of stay, etiology of cirrhosis, concomitant infection, ammonia level, history of bleeding in the last 12 mo, etiology of HE, intensive care unit (ICU) stay, and patient expiration, were collected. The degree of HE was determined from subjective and objective portions of hospital admission notes using the West Haven Criteria. Grade I included lack of trivial awareness, presence of euphoria and/or anxiety, shortened attention span and/or altered sleep rhythm. Patients met Grade II if they were lethargic, had personality changes, disorientation to time, dyspraxia and/or asterixis on physical exam. Grade III encephalopathy included confusion, disorientation to space, somnolence or signs of semi-stupor. Finally, Grade IV was defined as coma. The institutional review board at UMass Medical School/UMass Memorial Medical Center approved this study.

Definition of events and study outcomes

The primary outcome of the study was to evaluate the grade of HE in PPI users *versus*

non-users at the time of admission to the hospital and throughout their hospital course. Secondary outcomes included rate of infection, GI bleeding within the last 12 mo, mean ammonia level, and MELD scores at admission.

Statistical analysis

Data was analyzed using R version 3.3.2 GUI 1.68 Mavericks built for Mac computer. The statistical significance of between-cohort differences in categorical variables was tested using the chi-square test and in continuous variables using the two-sample t-test. All tests were two-tailed with a significance level of $P < 0.05$. Multivariate analysis using a linear regression model was applied to primary and secondary endpoints to determine statistically significant differences between PPI users and non-users. The threshold for statistical significance was set at P values < 0.05 .

RESULTS

Demographics and clinical characteristics

A total of 103 patients were included in this study from UMass Memorial Medical Center between January 2013 and December 2016. All patients had been diagnosed with liver cirrhosis based on imaging studies (U/S, computer scanning or magnetic resonance imaging) or liver biopsy and evidence of portal hypertension based on clinical signs, imaging or portal pressure measurement. Seventy-five (73%) of these cirrhosis patients were taking PPIs (PPI user), while twenty-eight (27%) patients with cirrhosis were not taking PPIs prior to enrollment (PPI non-user). The mean age of patients included in this study was 58.3 years, with the PPI user group being 59.6 years and in the PPI nonuser group being 55.3 years ($P = 0.044$). With regards to gender, males represented 54 (63.5%) patients in the PPI user group and 17 (47.2%) in PPI nonuser group ($P = 0.143$). Sixty-three (74.1%) patients were on lactulose in the PPI user group compared to 9 (80%) in the PPI nonuser group ($P = 0.599$).

Primary outcomes

The primary outcomes of this study were the grade of HE and hospital course for PPI users compared to non-users. The grade of HE using the West Haven Criteria was 2.3 in the PPI group compared to 1.7 in the PPI nonuser group, which represented a statistically significant difference ($P = 0.001$) (Table 1). With regards to hospital course, several outcomes were analyzed. The average length of hospital stay in the PPI group was 8.3 d compared to 6.5 d in PPI nonusers ($P = 0.046$). Twenty-seven patients (31.8%) in the PPI user group required an ICU admission during their hospital course compared to 6 in the PPI nonuser group (16.7%) ($P = 0.138$). Finally, 10 (11.8%) patients in the PPI group expired during their hospital stay compared to 1 in the PPI nonuser group (2.8%) ($P = 0.220$).

Secondary outcomes

Several secondary outcomes including infections, serum ammonia levels, MELD and GI bleeding were measured to further determine the effects of long-term PPI use in the cirrhotic population. With regards to infections, 5 patients (5.9%) in the PPI group developed *Clostridium difficile* compared to 0 in the PPI nonuser group (0%) ($P = 0.324$). Ten patients (11.8%) of the PPI group developed pneumonia compared to 1 in the PPI nonuser group (2.8%) ($P = 0.220$). Five patients in the PPI group developed spontaneous bacterial peritonitis compared to 4 in the PPI nonuser group (11.1%) ($P = 0.533$). The mean ammonia level of the PPI group on admission to the hospital was significantly higher, 67.8 mg/dL compared to 45.5 mg/dL in the PPI non-user group ($P = 0.095$). The mean MELD for the PPI group was 19.7 compared to 20.3 in the PPI nonuser group ($P = 0.687$). Twenty-six patients (30.6%) in the PPI group were admitted to the hospital for a GI bleed within the year prior to admission compared to 13 (36%) in the PPI nonuser group ($P = 0.703$) (Table 2).

Linear regression model

The multiple linear regression models showed that PPI use was associated with a higher grade of HE in cirrhosis compared to no PPI use. After adjustment for age, sex, MELD score, and lactulose use, the association between PPI use and HE grade was maintained ($P < 0.001$), with a beta of 0.607 and standard error of 0.179. In addition, a higher MELD score was also associated with a higher HE grade, with a beta of 0.024 and standard error of 0.011 ($P = 0.041$) (Table 3).

DISCUSSION

Table 1 Grade of hepatic encephalopathy in proton pump inhibitor users versus nonusers

| Grade of HE | PPI user | PPI nonuser |
|-------------|-----------|-------------|
| | n = 75 | n = 28 |
| Grade 1 | 15 (20.0) | 11 (39.3) |
| Grade 2 | 32 (46.6) | 13 (46.4) |
| Grade 3 | 18 (24.0) | 4 (14.3) |
| Grade 4 | 10 (13.4) | 0 (0) |

n (%), Grade of hepatic encephalopathy (HE) is defined by the West Haven Criteria Severity Scale for HE: Grade I (mild confusion, disordered sleep), II (lethargy moderate confusion), III (marked confusion, incoherent speech), IV (coma). HE: Hepatic encephalopathy; PPI: Proton pump inhibitor.

Because of their effectiveness in suppressing gastric acid secretions, PPIs have become one of the most commonly prescribed drug classes with annual expenditures in 2009 estimated at \$13 billion in the United States and \$24 billion worldwide^[19]. The first PPI available was omeprazole [Prilosec, Prilosec OTC, Zegerid, Zegerid OTC Losec in Canada], which served as a basis for all other PPIs in its mechanism of action by causing irreversible inhibition of H⁺/K⁺ ATPase, therefore halting hydrogen ion expulsion into the gastric lumen. While many studies have confirmed PPIs to be safe, our study indicates that in cirrhosis patients, the use of PPIs is associated with worsened hospital outcomes.

In this study, we found that hospitalized cirrhotic patients on a PPI had a significantly higher average West Haven Criteria for HE (score of 2.3) compared to patients who were not on a PPI (scored an average of 1.7, $P = 0.001$). Using linear regression models, we showed that patients using PPIs had a higher West Haven Criteria grade HE regardless of age, sex, MELD score, and/or lactulose use. Other statistically significant differences between the PPI user and non-user groups included longer length of hospital stay (8.5 d for PPI users *vs* 6.5 for PPI nonusers, $P = 0.046$). In alignment with patients having a higher grade of HE as well as a longer length of hospital stay, a greater percentage of patients in the PPI user group also had an ICU admission, indicating the greater extent of systemic involvement in this group. A recent meta-analysis by Bian *et al*^[20] supports our contention that there is a higher risk of developing HE in PPI users with liver dysfunction.

Prior studies have also indicated that PPI use could worsen HE in cirrhotic patients. A dose response analysis by Tsai *et al*^[21] stratified patients based on length of PPI use and showed that longer PPI use led to higher rates of HE. The result remained statistically significant after adjustment of patient comorbidities. Hung *et al*^[22] showed that cirrhotic patients on a PPI with HE had higher mortality rates at 30 d, 90 d and one year compared to cirrhotic patients with HE not on PPIs. This study investigates whether PPI use in HE patients predisposes them to more severe stages of HE as defined by the West Haven Criteria. Our analysis shows that patients on a PPI had significantly higher West Haven Criteria scale episode of HE compared to those not on a PPI (2.3 *vs* 1.7, $P = 0.001$). In addition, our study shows that PPIs predispose cirrhotic patients towards worsened encephalopathy regardless of age, sex, MELD score, or lactulose use.

The exact pathophysiology of HE is still not fully understood. Multiple mechanisms of action have been hypothesized and investigated, including the role of ammonia, increased GABA receptors in the brain, and accumulation of endogenous opioids^[23]. Overall, it appears that HE is multifactorial, with accumulation of ammonia being a leading cause of overt HE^[24]. In fact, studies have shown that HE ammonia levels are increased in 90% of patients. The primary source of ammonia in the body is the GI tract as a byproduct of chronic bacterial colonization, by enterocytes as they transform glutamine into ammonia, and by *H. pylori*, which metabolizes urea into ammonia. However, *H. pylori*'s role in HE is still unclear^[25,26].

One of the secondary endpoints in this study was determining the risk for infection in patients with cirrhosis on a PPI. Our data shows that patients on a PPI may have higher rates of *C. difficile* infection, pneumonia and spontaneous bacterial peritonitis. However, these results were not statistically significant with P -values of 0.324, 0.220 and 0.533, respectively. This is thought to be due to this study's small sample size of 103 patients. A recent meta-analysis by Lambert *et al*^[27] again demonstrated the association of community acquired pneumonia and *Clostridium difficile*-associated diarrhea (CDAD) with the use of PPI. The most likely pathogenesis of the development of these infections has been attributed to direct acid suppression in the

Table 2 Participant characteristics

| Variables | Total, n = 103 | PPI user, n = 75 | PPI nonuser, n = 28 | P value |
|--|----------------|------------------|---------------------|--------------------|
| Age, yr, Mean ± SD | 58.3 (10.8) | 59.6 (10.6) | 55.3 (10.7) | 0.044 ^a |
| Sex, male, n (%) | 71 (58.7) | 54 (63.5) | 17 (47.2) | 0.143 |
| On lactulose, n (%) | 92 (76) | 63 (74.1) | 29 (80) | 0.599 |
| Bleeding in last 12 mo, n (%) | 39 (32.2) | 26 (30.6) | 13 (36.1) | 0.703 |
| Infection, n (%) | | | | |
| <i>Clostridium difficile</i> colitis | 5 (4.1) | 5 (5.9) | 0 (0) | 0.324 |
| Pneumonia | 11 (9.1) | 10 (11.8) | 1 (2.8) | 0.220 |
| Spontaneous bacterial peritonitis | 9 (7.4) | 5 (5.9) | 4 (11.1) | 0.533 |
| Serum ammonia level, Mean ± SD | 61.1 (67.2) | 67.8 (67.8) | 45.5 (64.2) | 0.095 |
| Grade of hepatic encephalopathy, Mean ± SD | 2.1 (0.9) | 2.3 (0.9) | 1.7 (0.7) | 0.001 ^b |
| MELD score, Mean ± SD | 19.9 (7.2) | 19.7 (7.4) | 20.3 (6.7) | 0.687 |
| Length of stay in d, Mean ± SD | 8.5 (7.0) | 8.3 (7.9) | 6.5 (3.7) | 0.046 ^a |
| Required ICU, n (%) | 33 (27.3) | 27 (31.8) | 6 (16.7) | 0.138 |
| Expired, n (%) | 11 (9.1) | 10 (11.8) | 1 (2.8) | 0.220 |

^a*P* < 0.05.^b*P* < 0.01. MELD: Model for end-stage liver disease; ICU: Intensive care unit.

stomach and small bowel. With regards to CDAD, Janarthanan *et al*^[28] suggested that the alkaline status of the stomach (pH > 5) likely predisposes the patient to enhanced survival of *C. difficile* vegetative spores. A recent study in 2018 by Naito *et al*^[29] confirms our notion that continued PPI use leads to intestinal dysbiosis. Using 16S rRNA gene sequencing, PPIs were found to significantly increase certain enteric microbe taxonomy, including *Streptococcaceae* and *Enterococcaceae*, which are risk factors for CDAD, and to decrease *Faecalibacterium*, a commensal anti-inflammatory microbe present in human models.

Our paper has several limitations. First, because it is a retrospective review, information collection is incomplete, particularly regarding follow-up evaluation. Secondly because, we had an uneven distribution of the number of patients in the PPI use and non-use groups. Finally, due to the small sample size used for our study, several of our secondary outcomes were not statistically significant, including several infections and ICU admission rate, likely secondary to a lack of power. Again, as with any retrospective study, it is important to note that this type of study is unable to define exact causality. Further randomized, controlled, prospective studies are needed to help confirm the observation seen in our study.

In conclusion, PPIs are commonly prescribed for many GI diseases including GERD, peptic ulcer disease, and gastritis. They are often used without regard for their adverse effects. Our study demonstrates that PPI use in cirrhotic patients is associated with more severe degree of HE compared to those not on a PPI. Our data also showed that PPI use in this population was associated with a longer hospital stay and higher percentage of patients requiring an ICU admission. We suggest reducing PPI use in the cirrhotic population as a means to reduce episodes of HE. Further randomized-controlled, prospective studies are needed to help confirm this observation.

Table 3 Linear regression models, grade of hepatic encephalopathy

| Variables | B ± SE | P value |
|--------------------------------|----------------|----------------------|
| Model 1, demographic variables | | |
| Age | -0.001 ± 0.001 | 0.871 |
| Sex | 0.062 ± 0.167 | 0.710 |
| PPI use | 0.607 ± 0.180 | 0.001 ^b |
| Model 2, medical comorbidities | | |
| Age | 0.002 ± 0.008 | 0.787 |
| Sex | 0.043 ± 0.166 | 0.797 |
| MELD Score | 0.020 ± 0.011 | 0.079 |
| PPI Use | 0.607 ± 0.179 | < 0.001 ^b |
| Model 3, other medications | | |
| Age | 0.004 ± 0.008 | 0.647 |
| Sex | 0.033 ± 0.164 | 0.839 |
| MELD Score | 0.024 ± 0.011 | 0.041 ^a |
| Lactulose | 0.324 ± 0.189 | 0.089 |
| PPI use | 0.625 ± 0.178 | < 0.001 ^b |

^a*P* < 0.05,

^b*P* < 0.01. B ± SE: beta ± standard error. MELD: Model for end-stage liver disease; PPI: Proton pump inhibitor.

ARTICLE HIGHLIGHTS

Research background

Proton pump inhibitors (PPIs) are a recent hot topic in both internal medicine and gastroenterology, mostly because of their widespread use. Studies are quickly demonstrating that these medications may not come without risk, as recent studies have demonstrated a clear association between PPI and conditions like osteoporosis, pneumonia, *Clostridium difficile*, and some even postulate an association with dementia. While many effects of PPIs are still in question, it has also been shown that PPIs work by acid suppression, which can disrupt the gut microbiome. Patients with cirrhosis are at risk to develop hepatic encephalopathy (HE), primarily through ammonia produced by typical gut flora, and could subsequently be at risk for changes in this condition if the microbiome is altered in any way.

Research motivation

The main topic we are trying to address is whether PPI overuse can lead to additional effects aside from those previously mentioned and described in the literature. One particularly vulnerable population is those with cirrhosis, as ammonia production is affected by the gut microbiome. Solving this problem would allow future therapeutics to focus on the gut-liver-microbiome axis to prevent or lessen the severity of HE.

Research objectives

The main objective we want to demonstrate is the effect of PPI on the degree of HE. We hope to draw an association between PPIs and HE to encourage further prospective research studies on the side effects of PPIs, the gut microbiome in relation to HE, and to further aid in hospital outcomes for patients with cirrhosis.

Research methods

This is a retrospective analysis of patients with liver cirrhosis who were admitted with an ICD-9 and/or ICD-9 diagnosis of HE. Once these patients were identified, a chart analysis was performed to determine if these patients were on a PPI for > 30 d prior to their hospital admission. Those who were on a PPI for > 30 d were compared to patients who were not on a PPI at all in relation to their hospital stay. A linear regression model was applied to all patients to confirm the absence of any confounding variables.

Research results

During our analysis, we found that patients on a PPI who were admitted with HE subsequently had a significantly longer hospital stay, significantly worse grade of HE, and a larger percentage of those had intensive care unit (commonly known as ICU) admissions during their hospital stay. These findings suggest that patients should be assessed for the need for PPIs at every visit. This also points to the gap in knowledge between PPI and HE, especially if future research is able to demonstrate changes in the gut microbiome in patients on PPIs.

Research conclusions

In summary, in this retrospective medical chart review, PPI use was shown to be associated with worsened HE, greater length of hospital stays, and higher rate of ICU admissions in cirrhotic patients. To our knowledge, this is the first study that demonstrated that PPI use is associated with worse grades of HE, whereas prior studies by Tsai *et al* and Hung *et al* demonstrated higher risk of HE and overall higher mortality, respectively, in an Asian population. We propose that PPI use might affect cirrhotic patients by altering gastric pH, leading to the proliferation of gut micro-biome, thereby increasing ammonia production and bacterial translation. Considering the recent increased prevalence of PPIs, this study provides clinically relevant information regarding their potential risks in the cirrhotic population.

Research perspectives

As a retrospective review, our study is limited by incomplete data collection and uneven distribution of PPI user and non-user groups. However, the observation that PPI users experience worsen HE and longer hospital stays is clinically important. Future randomized-controlled studies will help confirm this observation and guide clinicians in a shift away from the use of PPI in cirrhotic patients.

REFERENCES

1. **Heidelbaugh JJ**, Bruderly M. Cirrhosis and chronic liver failure: part I. Diagnosis and evaluation. *Am Fam Physician* 2006; **74**: 756-762 [PMID: [16970019](#)]
2. **Adams RD**, Foley JM. The neurological disorder associated with liver disease. *Res Publ Assoc Res Nerv Ment Dis* 1953; **32**: 198-237 [PMID: [13134644](#)]
3. **Hadjihambi A**, Arias N, Sheikh M, Jalan R. Hepatic encephalopathy: a critical current review. *Hepatol Int* 2018; **12**: 135-147 [PMID: [28770516](#) DOI: [10.1007/s12072-017-9812-3](#)]
4. **Vilstrup H**, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, Weissenborn K, Wong P. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. *Hepatology* 2014; **60**: 715-735 [PMID: [25042402](#) DOI: [10.1002/hep.27210](#)]
5. **Strauss E**, da Costa MF. The importance of bacterial infections as precipitating factors of chronic hepatic encephalopathy in cirrhosis. *Hepatogastroenterology* 1998; **45**: 900-904 [PMID: [9684155](#)]
6. **Olde Damink SW**, Dejong CH, Jalan R. Review article: hyperammonaemic and catabolic consequences of upper gastrointestinal bleeding in cirrhosis. *Aliment Pharmacol Ther* 2009; **29**: 801-810 [PMID: [19183148](#) DOI: [10.1111/j.1365-2036.2009.03938.x](#)]
7. **Blei AT**, Córdoba J; Practice Parameters Committee of the American College of Gastroenterology. Hepatic Encephalopathy. *Am J Gastroenterol* 2001; **96**: 1968-1976 [PMID: [11467622](#) DOI: [10.1111/j.1572-0241.2001.03964.x](#)]
8. **Assy N**, Rosser BG, Grahame GR, Minuk GY. Risk of sedation for upper GI endoscopy exacerbating subclinical hepatic encephalopathy in patients with cirrhosis. *Gastrointest Endosc* 1999; **49**: 690-694 [PMID: [10343210](#)]
9. **Butterworth RF**. Hepatic encephalopathy: a central neuroinflammatory disorder? *Hepatology* 2011; **53**: 1372-1376 [PMID: [21480337](#) DOI: [10.1002/hep.24228](#)]
10. **Gupta A**, Dhiman RK, Kumari S, Rana S, Agarwal R, Duseja A, Chawla Y. Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy. *J Hepatol* 2010; **53**: 849-855 [PMID: [20675008](#) DOI: [10.1016/j.jhep.2010.05.017](#)]
11. **Shaheen NJ**, Stuart E, Schmitz SM, Mitchell KL, Fried MW, Zacks S, Russo MW, Galanko J, Shrestha R. Pantoprazole reduces the size of postbanding ulcers after variceal band ligation: a randomized, controlled trial. *Hepatology* 2005; **41**: 588-594 [PMID: [15726658](#) DOI: [10.1002/hep.20593](#)]
12. **Yoshida N**, Yoshikawa T, Tanaka Y, Fujita N, Kassai K, Naito Y, Kondo M. A new mechanism for anti-inflammatory actions of proton pump inhibitors--inhibitory effects on neutrophil-endothelial cell interactions. *Aliment Pharmacol Ther* 2000; **14** Suppl 1: 74-81 [PMID: [10807407](#)]
13. **Bavishi C**, Dupont HL. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. *Aliment Pharmacol Ther* 2011; **34**: 1269-1281 [PMID: [21999643](#) DOI: [10.1111/j.1365-2036.2011.04874](#)]
14. **Norenberg MD**. Astrocytic-ammonia interactions in hepatic encephalopathy. *Semin Liver Dis* 1996; **16**: 245-253 [PMID: [8989810](#) DOI: [10.1055/s-2007-1007237](#)]
15. **Rama Rao KV**, Jayakumar AR, Norenberg DM. Ammonia neurotoxicity: role of the mitochondrial permeability transition. *Metab Brain Dis* 2003; **18**: 113-127 [PMID: [12822830](#)]
16. **Butterworth RF**, Giguère JF, Michaud J, Lavoie J, Layrargues GP. Ammonia: key factor in the pathogenesis of hepatic encephalopathy. *Neurochem Pathol* 1987; **6**: 1-12 [PMID: [3306479](#)]
17. **Albrecht J**, Jones EA. Hepatic encephalopathy: molecular mechanisms underlying the clinical syndrome. *J Neurol Sci* 1999; **170**: 138-146 [PMID: [10617392](#)]
18. **Suraweera D**, Sundaram V, Saab S. Evaluation and Management of Hepatic Encephalopathy: Current Status and Future Directions. *Gut Liver* 2016; **10**: 509-519 [PMID: [27377741](#) DOI: [10.5009/gnl15419](#)]
19. **Durand C**, Willett KC, Desilets AR. Proton Pump Inhibitor use in Hospitalized Patients: Is Overutilization Becoming a Problem? *Clin Med Insights Gastroenterol* 2012; **5**: 65-76 [PMID: [24833936](#) DOI: [10.4137/CGast.S9588](#)]
20. **Bian J**, Wang A, Lin J, Wu L, Huang H, Wang S, Yang X, Lu X, Xu Y, Zhao H. Association between proton pump inhibitors and hepatic encephalopathy: A meta-analysis. *Medicine (Baltimore)* 2017; **96**: e6723 [PMID: [28445288](#) DOI: [10.1097/MD.0000000000006723](#)]
21. **Tsai CF**, Chen MH, Wang YP, Chu CJ, Huang YH, Lin HC, Hou MC, Lee FY, Su TP, Lu CL. Proton Pump Inhibitors Increase Risk for Hepatic Encephalopathy in Patients With Cirrhosis in A Population Study. *Gastroenterology* 2017; **152**: 134-141 [PMID: [27639806](#) DOI: [10.1053/j.gastro.2016.09.007](#)]
22. **Hung WT**, Teng YH, Yang SF, Yeh HW, Yeh YT, Wang YH, Chou MY, Chou MC, Chan CH, Yeh CB. Association between Proton Pump Inhibitor Use and CNS Infection Risk: A Retrospective Cohort Study. *J Clin Med* 2018; **7**: 252 [PMID: [30200363](#) DOI: [10.3390/jcm7090252](#)]
23. **Bajaj JS**, Heuman DM, Hylemon PB, Sanyal AJ, White MB, Monteith P, Noble NA, Unser AB, Daita K, Fisher AR, Sikaroodi M, Gillevet PM. Altered profile of human gut microbiome is associated with

- cirrhosis and its complications. *J Hepatol* 2014; **60**: 940-947 [PMID: [24374295](#) DOI: [10.1016/j.jhep.2013.12.019](#)]
- 24 **Ong JP**, Aggarwal A, Krieger D, Easley KA, Karafa MT, Van Lente F, Arroliga AC, Mullen KD. Correlation between ammonia levels and the severity of hepatic encephalopathy. *Am J Med* 2003; **114**: 188-193 [PMID: [12637132](#)]
- 25 **Müting D**, Perisoara A, Baum G, Flaschoff HJ, Bucsis L. The role of protein metabolism in 204 liver cirrhotics with and without hepatic encephalopathy. II. Amino acids, free phenols and indoles. *Hepatogastroenterology* 1986; **33**: 66-70 [PMID: [3721389](#)]
- 26 **Prakash R**, Mullen KD. Mechanisms, diagnosis and management of hepatic encephalopathy. *Nat Rev Gastroenterol Hepatol* 2010; **7**: 515-525 [PMID: [20703237](#) DOI: [10.1038/nrgastro.2010.116](#)]
- 27 **Lambert AA**, Lam JO, Paik JJ, Ugarte-Gil C, Drummond MB, Crowell TA. Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis. *Plos One* 2015; **10**: e0128004 [PMID: [26042842](#) DOI: [10.1371/journal.pone.0128004](#)]
- 28 **Janarthanan S**, Ditah I, Adler DG, Ehrinpreis MN. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. *Am J Gastroenterol* 2012; **107**: 1001-1010 [PMID: [22710578](#) DOI: [10.1038/ajg.2012.179](#)]
- 29 **Naito Y**, Kashiwagi K, Takagi T, Andoh A, Inoue R. Intestinal Dysbiosis Secondary to Proton-Pump Inhibitor Use. *Digestion* 2018; **97**: 195-204 [PMID: [29316555](#) DOI: [10.1159/000481813](#)]



Published By Baishideng Publishing Group Inc
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-3991568
E-mail: bpgoffice@wjgnet.com
Help Desk: <https://www.f6publishing.com/helpdesk>
<https://www.wjgnet.com>

